GSK
GSK
804 hedge funds and large institutions have $11.2B invested in GSK in 2019 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 290 increasing their positions, 287 reducing their positions, and 92 closing their positions.
31% more call options, than puts
Call options by funds: $98M | Put options by funds: $74.7M
1% more repeat investments, than reductions
Existing positions increased: 290 | Existing positions reduced: 287
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
0.04% less ownership
Funds ownership: 4.52% → 4.48% (-0.04%)
5% less capital invested
Capital invested by funds: $11.7B → $11.2B (-$557M)
5% less funds holding
Funds holding: 847 → 804 (-43)
35% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$71.6M |
| 2 |
Renaissance Technologies
New York
|
+$39.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$33M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$190M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$68.4M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$28.9M |
| 4 |
Millennium Management
New York
|
-$28.2M |
| 5 |
MAM
Majedie Asset Management
London,
United Kingdom
|
-$18.1M |
GSK Hedge Fund Activity: Q2 2019 in Review
804 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2019, worth a combined $11.2B — down 4.8% from $11.7B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of GSK and 60 opened new positions — a net loss of 32 holders — while 287 trimmed existing stakes and 290 added.
The largest buyer was Jane Street, adding an estimated $71.6M. The largest seller was Arrowstreet Capital, cutting an estimated $190M.
- 804 institutional investors held GSK (GSK) as of Q2 2019, down from 847 in Q1 2019.
- Funds reported $11.2B of GSK stock for Q2 2019, down 4.8% quarter-over-quarter.
- 60 funds opened new GSK positions in Q2 2019 and 92 closed out, a net change of -32 holders.
- The largest GSK buyer in Q2 2019 was Jane Street, an estimated $71.6M added.
- The largest GSK seller in Q2 2019 was Arrowstreet Capital, an estimated $190M sold.
Based on aggregated 13F filings for Q2 2019.